CAP-XX Limited Portal Instruments Selects CAP-XX Supercapacitors
15 Marzo 2021 - 1:00AM
RNS Non-Regulatory
TIDMCPX
CAP-XX Limited
15 March 2021
REACH
15 March 2021
CAP-XX Limited
("CAP-XX" or the "Company")
Portal Instruments Selects CAP-XX Supercapacitors for
Needle-Free Jet Injection Platform
CAP-XX's ultra-thin prismatic supercapacitors, manufactured in
Australia and Malaysia, deliver burst power needed for high-speed
needle-free jet injection
Sydney, Australia - March 15, 2021 - CAP-XX Limited (LSE:CPX),
the leading manufacturer of ultra-thin prismatic and cylindrical
supercapacitors, announced that Portal Instruments, a clinical
stage medical device company, has selected the CAP-XX GS230F
supercap for its advanced needle-free drug delivery platform for
self-administering biological medicines. Portal Instruments chose
the CAP-XX prismatic supercapacitors, which are manufactured in
CAP-XX's production facilities in Australia and Malaysia, due to
their characteristic low Equivalent Series Resistance (ESR) which
enables the high burst of energy needed to drive the fast, large
volume needle-free jet injection, and for their thin form factor
which fits easily inside the small drug delivery device.
Portal Instruments' needle-free jet injection platform is
intended to simplify the drug delivery experience, from
self-injection for patients suffering from chronic disease, to
healthcare workers delivering vaccines. The handheld connected
device delivers injectable medications without a needle by
pressurizing the drug itself, which passes through a 160 um nozzle
to create a very fine fluid jet, about the size of a hair, at a
controlled speed. This jet pierces the skin, delivering the drug to
the target tissue in a fraction of a second, up to 30x faster than
a conventional autoinjector and with less pain. Portal's platform
can deliver injection volumes up to 2 mL, irrespective of drug
concentration and viscosity.
Portal Instruments uses multiple ultra-power-dense CAP-XX GS230F
supercapacitors to deliver hundreds of watts of output power to
drive the high-speed, concentrated injection in its compact
handheld device. CAP-XX's industry-leading power density enables
the device's small, easy-to-use form factor and allows the device
to operate from a compact, industry-standard rechargeable battery
which recharges the supercapacitors before every injection.
The CAP-XX GS230F supercapacitor features:
-- 1200 mF
-- 5 V
-- 39 x 17 x 3.9 mm
-- Very very low ESR of 25 m (milliohm) which is critical in
this fast drug delivery application
-- Very low leakage current of 2.5 uA (micro-Amps)
"Our vision is a needle free world," said Patrick Anquetil,
Portal Instruments' CEO. "The CAP-XX supercapacitor is a key
enabler in delivering a fast, concentrated injection that is over
within half a second, empowering the patient to more comfortably
manage their chronic condition."
"We are proud to provide the high-density power Portal
Instruments needs to inject high viscosity biologics without the
pain and anxiety of needles," said Anthony Kongats, CEO at CAP-XX.
"Their needle-free breakthrough technology can bring welcome relief
to self-injecting diabetic, arthritis and IVF patients, and mass
vaccination sites around the world. This is just one example of the
many possible applications for CAP-XX's thin supercapacitors in
medical devices."
For further information contact:
CAP-XX Limited
Anthony Kongats (Chief Executive Officer) +61(0)2 9420 0690
Kreab (Financial PR)
Robert Speed +44 (0) 20 7074 1800
Allenby Capital (Nominated Adviser and Broker +44 (0) 20 3328
5656
David Hart / Alex Brearley (Corporate Finance)
Tony Quirke (Sales and Corporate Broking)
About CAP-XX
CAP-XX (LSE:CPX) is a world leader in the design and manufacture
of ultra-thin prismatic and compact cylindrical supercapacitors.
Its prismatic supercapacitors are manufactured in Australia and
Malaysia and its cylindrical supercapacitors are manufactured in
China. The company's strong intellectual property (IP) portfolio
includes 21 patents worldwide. CAP-XX's ultra-thin prismatic
supercapacitors are ideal for space-constrained electronics
applications where small energy storage device size and thickness
are important. The unique feature of CAP-XX supercapacitors is
their very high-power density and high-energy storage capacity in
space-efficient thin prismatic and compact cylindrical packages.
For more information about CAP-XX, visit https://www.cap-xx.com/ or
email sales@cap-xx.com.
About Portal Instruments
In partnership with biopharmaceutical firms, Portal Instruments
is developing and commercializing a highly innovative needle-free
drug delivery platform technology to transform the administration
of medicines and improve the patient experience for chronic
diseases. Portal's needle-free delivery technology is derived from
research at the Massachusetts Institute of Technology (MIT) and
enables the administration of high viscosity biologic drugs with
less discomfort and without the anxiety of handling needles. Real
time tracking and reporting sets a new standard for monitoring
adherence and potentially improving patient outcomes. Portal
Instruments is ISO 13485:2016 certified. For more information,
please visit: www.portalinstruments.com or follow @portalcambridge
on Twitter.
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFUFULEFSEID
(END) Dow Jones Newswires
March 15, 2021 03:00 ET (07:00 GMT)
Cap-xx (LSE:CPX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cap-xx (LSE:CPX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024